The DOI matches its Crossref record; 197 of the 197 references it cites were found in a registry or an index.
Nanoparticle Vaccines Against Infectious Diseases
Open accessAbstract
Due to emergence of new variants of pathogenic micro-organisms the treatment and immunization of infectious diseases have become a great challenge in the past few years. In the context of vaccine development remarkable efforts have been made to develop new vaccines and also to improve the efficacy of existing vaccines against specific diseases. To date, some vaccines are developed from protein subunits or killed pathogens, whilst several vaccines are based on live-attenuated organisms, which carry the risk of regaining their pathogenicity under certain immunocompromised conditions. To avoid this, the development of risk-free effective vaccines in conjunction with adequate delivery systems are considered as an imperative need to obtain desired humoral and cell-mediated immunity against infectious diseases. In the last several years, the use of nanoparticle-based vaccines has received a great attention to improve vaccine efficacy, immunization strategies, and targeted delivery to achieve desired immune responses at the cellular level. To improve vaccine efficacy, these nanocarriers should protect the antigens from premature proteolytic degradation, facilitate antigen uptake and processing by antigen presenting cells, control release, and should be safe for human use. Nanocarriers composed of lipids, proteins, metals or polymers have already been used to attain some of these attributes. In this context, several physico-chemical properties of nanoparticles play an important role in the determination of vaccine efficacy. This review article focuses on the applications of nanocarrier-based vaccine formulations and the strategies used for the functionalization of nanoparticles to accomplish efficient delivery of vaccines in order to induce desired host immunity against infectious diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Feng, G., Jiang, Q., Xia, M., Lu, Y., Qiu, W., Zhao, D., Lu, L., Peng, G., & Wang, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061135 · Cited by 108
RetractedA study of the nucleation and growth processes in the synthesis of colloidal gold
Turkevich, J., Stevenson, P. C., & Hillier, J. (1951) · Discussions of the Faraday Society · doi:10.1039/df9511100055 · Cited by 7,792
Understanding biophysicochemical interactions at the nano–bio interface
Nel, A. E., Mädler, L., Velegol, D., Xia, T., Hoek, E. M. V., Somasundaran, P., Klaessig, F., Castranova, V., & Thompson, M. (2009) · Nature Materials · doi:10.1038/nmat2442 · Cited by 7,083
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,950
Neutrophil recruitment and function in health and inflammation
Kolaczkowska, E., & Kubes, P. (2013) · Nature Reviews Immunology · doi:10.1038/nri3399 · Cited by 5,472
Toll-like receptors and their crosstalk with other innate receptors in infection and immunity
Kawai, T., & Akira, S. (2011) · Immunity · doi:10.1016/j.immuni.2011.05.006 · Cited by 3,658 · cited 2×
“Conjugation of CD47 molecules on the surface of NPs modulated the down-stream signaling cascades and also reduced NP internalization by phagocytic cells (131).”
BackgroundPathogen Recognition and Inflammatory Signaling in Innate Immune Defenses
Mogensen, T. H. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00046-08 · Cited by 3,111
Effect of Surface Properties on Nanoparticle–Cell Interactions
Verma, A., & Stellacci, F. (2010) · Small · doi:10.1002/smll.200901158 · Cited by 2,619
Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein
Ulmer, J. B., Donnelly, J. J., Parker, S. E., Rhodes, G. H., Felgner, P. L., Dwarki, V. J., Gromkowski, S. H., Deck, R. R., DeWitt, C. M., Friedman, A., et al. (1993) · Science · doi:10.1126/science.8456302 · Cited by 2,318
Protein-nanoparticle interactions
Lynch, I., & Dawson, K. A. (2008) · Nano Today · doi:10.1016/s1748-0132(08)70014-8 · Cited by 1,727
Cited by
Nanotechnology for COVID-19: Therapeutics and Vaccine Research
Chauhan, G., Madou, M. J., Kalra, S., Chopra, V., Ghosh, D., & Martinez-Chapa, S. O. (2020) · ACS Nano · doi:10.1021/acsnano.0c04006 · Cited by 385
COVID-19 vaccines: The status and perspectives in delivery points of view
Chung, J. Y., Thone, M. N., & Kwon, Y. J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.011 · Cited by 375
COVID-19 Vaccine Frontrunners and Their Nanotechnology Design
Chung, Y. H., Beiss, V., Fiering, S. N., & Steinmetz, N. F. (2020) · ACS Nano · doi:10.1021/acsnano.0c07197 · Cited by 346
Emerging Concepts and Technologies in Vaccine Development
Brisse, M., Vrba, S. M., Kirk, N., Liang, Y., & Ly, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.583077 · Cited by 323
Gaur, M., Misra, C., Yadav, A. B., Swaroop, S., Maolmhuaidh, F. Ó., Bechelany, M., & Barhoum, A. (2021) · Materials · doi:10.3390/ma14205978 · Cited by 317
Liposomes used as a vaccine adjuvant-delivery system: From basics to clinical immunization
Wang, N., Chen, M., & Wang, T. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.04.025 · Cited by 308
Protein-based antigen presentation platforms for nanoparticle vaccines
Nguyen, B., & Tolia, N. H. (2021) · npj Vaccines · doi:10.1038/s41541-021-00330-7 · Cited by 271
Nanotechnology-Based Strategies to Overcome Current Barriers in Gene Delivery
Mirón-Barroso, S., Domènech, E. B., & Trigueros, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168537 · Cited by 91
Metadata
- Authors
- Pati, R., Shevtsov, M., & Sonawane, A.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2018-10-04
- Volume
- 9
- Pages
- 2224-2224
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2895497426
- Cited by
- 514
- References
- 197
- FWCI
- 16.22
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.